drug
Immuno-oncology
Preclinicalupdated 6mo agoby American Gene Technologies International Inc
Preclinicalcommunity read0 votes
indications
indications
Breast CancerProstate Cancer
all catalysts(0)
nothing on the calendar yet
Trials studying Immuno-oncology
- —Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%
- phase2Safety and Efficacy Study of IMSA101 in Refractory Malignancies
- —Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC
News(10)
- FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF classThe FDA has issued a complete response letter to Summit Therapeutics, derailing the immediate U.S. launch of a drug class that many industry heavyweights believe could eventually dethrone Merck & C…fiercebiotech · 3d ago
- BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’BioNTech has agreed to pay $205 million to purchase an FDA priority review voucher to support a future filing of a drug in its “late-stage oncology pipeline.” Fierce breaks down which candidate is…fiercebiotech · 6d ago
- Beyond the needle: The future of intratumoral therapyIn this episode of Denatured, you’ll hear from from Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak, president, CEO and board director at Candel Therapeutics. We explore how intratum…biospace · 12d ago
- Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdictWith companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics’ Akeso-partnered PD-1xVEGF antibody, one analyst calls the asset “the next major bac…biospace · 15d ago
- Astellas bets up to $1.34B for option to advance Audax immuno-oncology assetAstellas Pharma could secure the exclusive global rights to Audax Biosciences’ DAX-044, an antibody-cytokine fusion therapy that activates the immune system in the vicinity of the tumor.biospace · 19d ago
- Astellas buys option on preclinical IL-12 cancer drug from Audax BiosciencesAstellas has taken an exclusive option to license a preclinical immuno-oncology asset from Australian biotech Audax Biosciences. The deal features $285 million that covers the upfront fee and a pay…endpoints · 20d ago
- Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woesAstellas has struck a deal for Audax Biosciences’ IL-12 program, committing up to $285 million in upfront and option fees to secure a chance to license the preclinical immuno-oncology program.fiercebiotech · 20d ago
- ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancerSac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial cancer by 6.9 months over chemotherapy in a Phase 3 trial—becoming the first…biospace · 21d ago
- ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leakAfter sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, analysts are more keen on the personalized mRNA cancer vaccine data that last w…biospace · 21d ago
- Roche taps Zymeworks in up to $813M deal for preclinical T cell engagerAnother day, another Roche deal. The Swiss pharma is teaming up with Zymeworks, paying $55 million upfront for worldwide rights to a trispecific T cell engager (TCE) that could go head-to-head with…endpoints · 24d ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that